Xvivo Perfusion AB (OSTO:XVIVO) Total Liabilities : kr250.5 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Xvivo Perfusion AB Total Liabilities?

Xvivo Perfusion AB's Total Liabilities for the quarter that ended in Mar. 2024 was kr250.5 Mil.

Xvivo Perfusion AB's quarterly Total Liabilities declined from Sep. 2023 (kr308.99 Mil) to Dec. 2023 (kr250.57 Mil) and declined from Dec. 2023 (kr250.57 Mil) to Mar. 2024 (kr250.54 Mil).

Xvivo Perfusion AB's annual Total Liabilities increased from Dec. 2021 (kr257.15 Mil) to Dec. 2022 (kr302.95 Mil) but then declined from Dec. 2022 (kr302.95 Mil) to Dec. 2023 (kr250.57 Mil).

Xvivo Perfusion AB Total Liabilities Historical Data

The historical data trend for Xvivo Perfusion AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Total Liabilities Chart

Xvivo Perfusion AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

56.97

141.85

257.15

302.95

250.57

Xvivo Perfusion AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															292.99	285.10	308.99	250.57	250.54

Xvivo Perfusion AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Xvivo Perfusion AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	134.488	+	(21.169	+	94.909
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	250.6

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2195.611	-	1945.045
	=	250.6

Xvivo Perfusion AB's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	199.8	+	(19.914	+	30.828
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	250.5

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	2253.686	-	2003.144
	=	250.5

Xvivo Perfusion AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Xvivo Perfusion AB (OSTO:XVIVO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OSTO:XVIVO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

XVIPF:USA 3XV:Germany

Address

Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (OSTO:XVIVO) Headlines

No Headlines